A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Bristol-Myers Squibb1,500 enrolled

Overview

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Psoriasis

Interventions

DeucravacitinibDRUG

As prescribed by treating clinician

ApremilastDRUG

As prescribed by treating clinician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have been diagnosed with plaque psoriasis by a dermatologist * Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) * Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: * Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) * Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

Locations (1)

Local Institution

Waltham, Massachusetts, United States

RECRUITING

Outcomes

Primary Outcomes

Change in body surface area (BSA)

Time frame: At baseline and every 6 months up to 60 months or treatment discontinuation

Investigator global assessment (IGA) response 0/1

Time frame: Up to 60 months

Dermatology life quality index (DLQI) response 0/1

Time frame: Up to 60 months

Time from date of treatment initiation to date of discontinuation

Time frame: Up to 60 months